TY  - JOUR
AU  - Le Rhun, Emilie
AU  - Sain, Debaleena
AU  - Erridge, Sara C
AU  - Reardon, David A
AU  - Minniti, Giuseppe
AU  - Roth, Patrick
AU  - Wick, Wolfgang
AU  - Nabors, Burt
AU  - Sampson, John
AU  - Mason, Warren
AU  - Cloughesy, Tim
AU  - Reijneveld, Jacob C
AU  - Stupp, Roger
AU  - Preusser, Matthias
AU  - Gorlia, Thierry
AU  - Weller, Michael
TI  - Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.
JO  - JAMA network open
VL  - 8
IS  - 11
SN  - 2574-3805
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2025-02624
SP  - e2545578 -
PY  - 2025
AB  - Proton pump inhibitors (PPI) are often prescribed to prevent steroid-induced gastritis and peptic ulcer disease in patients with glioblastoma. Yet, these drugs may enhance the activity of aldehyde dehydrogenase 1 A1 (ALDH1A1), which has been linked to protection from oxidative stress, radiotherapy, and chemotherapy.To explore the associations of the use of potent ALDH1A1-activating PPIs (PA-PPIs) and other antacid drugs with outcomes in patients with newly diagnosed glioblastoma.This meta-analysis was a secondary analysis of individual prospectively captured patient data using a dataset of 5 randomized clinical trials conducted between 2008 and 2020. Participants included patients with a new diagnosis of glioblastoma. Data analysis was completed in November 2024.We assessed drug use at baseline and defined 3 landmarks: start of temozolomide maintenance cycles 1 (landmark 1) and 4 (landmark 2), and end of cycle 6 (landmark 3).The primary outcome measures were progression-free survival (PFS) and overall survival (OS) from baseline and from the start of each corresponding landmark time.The study population included 2981 patients (1858 [62.3
KW  - Humans
KW  - Glioblastoma: mortality
KW  - Glioblastoma: drug therapy
KW  - Proton Pump Inhibitors: therapeutic use
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Aged
KW  - Adult
KW  - Brain Neoplasms: mortality
KW  - Brain Neoplasms: drug therapy
KW  - Temozolomide: therapeutic use
KW  - Proton Pump Inhibitors (NLM Chemicals)
KW  - Temozolomide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41288972
DO  - DOI:10.1001/jamanetworkopen.2025.45578
UR  - https://inrepo02.dkfz.de/record/306583
ER  -